NCT06863402View on ClinicalTrials.gov

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

April 1, 2029

Study Completion Date

April 1, 2030

Conditions
Richter SyndromeDiffuse Large B-Cell LymphomaChronic Lymphocytic Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo PET/CT or CT

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Nemtabrutinib

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER